All articles tagged with #optic nerve
Scientists report that epigenetic reprogramming to revive youthful cellular memory in aging eye cells has reached humans, with the first patient treated in a Phase 1 trial for glaucoma and other optic neuropathies. The approach could someday restore some lost vision, but safety, delivery, and how durable the effects are remain major hurdles before it becomes a widely available therapy.
Scientists have begun the first human trial of partial cellular reprogramming to nudge aging eye cells toward a younger state in hopes of regenerating optic nerve neurons to treat glaucoma. The study by Life Biosciences treated the first participant and plans to enroll up to 12 total; this is an early, experimental approach—not a lifespans therapy—with cancer risk as a key concern and no results yet.
Scientists have treated the first participant in an early-stage clinical trial testing partial cellular reprogramming to make aging cells act younger, aiming to regenerate optic nerve neurons in glaucoma. While promising, the approach is experimental, enrolling up to 12 participants, with potential cancer risk, and is not a universal anti-aging therapy.
The first participant has been treated in a landmark trial testing partial cellular reprogramming—activating three genes to make aged cells behave younger—in hopes of regenerating optic nerve neurons and treating glaucoma; safety is the primary focus, with low—but not zero—risk of cancer, and results will determine viability for broader use.
Surgeons at NYU Langone Health have successfully performed the world's first whole eye transplant, along with a face transplant, on a man who suffered extensive facial injuries and lost his left eye due to an accident with high-voltage power lines. While it is too early to determine if the patient will regain vision in his new eye, the transplant has yielded promising results so far, with the donated eye showing good blood flow and no signs of rejection. The surgery provides valuable insights into the healing process of the human eye and may pave the way for future advancements in treating blindness.
Surgeons at NYU Langone Health have successfully performed the world's first whole eye transplant, in addition to a face transplant, on a man who suffered extensive facial injuries and lost his left eye due to an accident with high-voltage power lines. While it is too early to determine if the patient will regain vision in his new eye, the transplant has yielded promising results so far, with the donated eye showing good blood flow and no signs of rejection. The surgery provides valuable insights into the healing process of the human eye and may contribute to advancements in the field of eye transplants and optic nerve repair.
Surgeons at NYU Langone Health have successfully performed the world's first transplant of an entire human eye, as part of a face transplant procedure. The patient, Aaron James, had suffered extensive facial injuries and lost one eye due to an accident with high-voltage power lines. While it is too early to determine if James will regain vision in his new eye, the surgery offers valuable insights into the healing process of the human eye. The transplant has defied expectations, with the donated eye showing good blood flow and no signs of rejection. Researchers are now studying scans of James's brain to understand the injured optic nerve, a crucial step in the quest to cure blindness.
Adding optic nerve damage, measured by the thickness of retinal layers in the eye, to the diagnostic criteria for multiple sclerosis (MS) can enhance diagnostic accuracy for individuals who have experienced a single MS-like event. Researchers believe their findings support the inclusion of the optic nerve in the next revision of the McDonald criteria, the gold standard for diagnosing MS. Optical coherence tomography (OCT) was used to track retinal nerve layer thickness in patients with clinically isolated syndrome (CIS), and the addition of OCT measures significantly improved diagnostic accuracy and sensitivity compared to traditional metrics. This could lead to earlier treatment initiation and improved long-term prognosis for MS patients.